Last 47 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 11.28 | 76.18 | 17.98 | — | 10.35 | 7.55 | 18.24 | 34.45 | 12.75 | 26.96 | 26.41 | — | 13.41 | 23.64 | 17.01 | 9.76 | 11.45 | 26.61 | 15.85 | 27.83 | 12.96 |
| — | +909.2% | -1.5% | — | -18.8% | -72.0% | -30.9% | — | -4.9% | +14.0% | +55.3% | — | +17.1% | -11.2% | +7.3% | -64.9% | -11.6% | -1.0% | -19.3% | -1.5% | -19.4% | |
| P/S Ratio | 1.86 | 2.08 | 2.58 | 2.42 | 2.21 | 2.78 | 3.23 | 3.96 | 2.55 | 2.67 | 3.12 | 2.55 | 2.65 | 3.16 | 3.13 | 2.65 | 1.81 | 2.91 | 3.19 | 3.02 | 2.79 |
| — | -25.3% | -20.0% | -38.8% | -13.3% | +4.1% | +3.4% | +55.1% | -3.6% | -15.5% | -0.3% | -3.6% | +45.9% | +8.3% | -1.9% | -12.2% | -35.0% | -20.1% | -8.3% | -3.5% | -12.4% | |
| P/B Ratio | 1.23 | 1.47 | 1.59 | 1.65 | 1.58 | 1.70 | 1.84 | 1.55 | 1.98 | 1.66 | 1.63 | 1.68 | 1.84 | 1.85 | 1.81 | 1.62 | 1.34 | 1.76 | 1.86 | 1.82 | 1.91 |
| — | -13.5% | -13.7% | +6.2% | -19.9% | +2.0% | +12.7% | -7.4% | +7.3% | -10.0% | -9.8% | +3.8% | +37.9% | +5.3% | -2.6% | -11.3% | -30.0% | -15.6% | -5.1% | -5.6% | -3.8% | |
| P/FCF | 8.54 | 6.54 | 17.24 | 18.63 | 6.34 | — | 16.35 | — | — | — | — | 6.80 | — | 13.94 | — | 5.52 | — | 11.14 | — | 6.72 | — |
| — | — | +5.4% | — | — | — | — | — | — | — | — | +23.1% | — | +25.1% | — | -17.9% | — | +26.3% | — | -56.3% | — | |
| EV / EBITDA | 6.50 | 10.16 | 11.64 | 35.05 | 7.92 | 17.03 | 14.24 | 42.00 | 8.78 | 16.55 | 18.91 | 36.71 | 9.44 | 15.37 | 12.59 | 6.79 | 7.49 | 18.42 | 12.16 | 18.25 | 9.56 |
| — | -40.3% | -18.3% | -16.6% | -9.8% | +2.9% | -24.7% | +14.4% | -7.0% | +7.7% | +50.1% | +440.9% | +25.9% | -16.6% | +3.6% | -62.8% | -21.6% | -0.5% | -13.5% | +90.9% | -9.7% | |
| EV / EBIT | 10.35 | 26.54 | 14.96 | 17.69 | 8.65 | 20.87 | 15.81 | 92.79 | 9.58 | 22.70 | 23.52 | — | 10.62 | 19.15 | 14.17 | 7.63 | 9.21 | 23.95 | 14.37 | 22.77 | 10.77 |
| — | +27.2% | -5.4% | -80.9% | -9.7% | -8.0% | -32.8% | — | -9.7% | +18.5% | +66.0% | — | +15.3% | -20.0% | -1.4% | -66.5% | -14.5% | +6.0% | -13.4% | +1.0% | -20.7% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.1% | 75.5% | 72.1% | 70.3% | 74.1% | 72.1% | 72.8% | 70.2% | 71.1% | 70.0% | 69.5% | 66.8% | 69.8% | 69.4% | 71.7% | 67.4% | 70.8% | 69.7% | 71.4% | 66.6% | 70.1% |
| — | +4.6% | -0.9% | +0.0% | +4.1% | +3.0% | +4.7% | +5.1% | +2.0% | +0.9% | -3.0% | -0.9% | -1.5% | -0.5% | +0.4% | +1.2% | +1.1% | +1.9% | +2.2% | +3.0% | +3.3% | |
| Operating Margin | 20.5% | 19.4% | 20.2% | -8.5% | 27.5% | 13.7% | 21.1% | 7.5% | 25.7% | 14.0% | 12.7% | 2.8% | 25.3% | 17.4% | 22.7% | 35.8% | 20.7% | 13.3% | 23.8% | 14.1% | 28.0% |
| — | +41.2% | -4.2% | -213.3% | +7.1% | -2.0% | +65.7% | +167.9% | +1.5% | -19.5% | -44.0% | -92.2% | +22.0% | +30.5% | -4.9% | +153.6% | -25.9% | -22.5% | +3.0% | -7.2% | +9.6% | |
| Net Margin | 16.7% | 2.8% | 14.4% | -6.6% | 21.3% | 36.7% | 17.7% | 6.5% | 19.9% | 9.8% | 11.6% | -4.5% | 19.9% | 13.4% | 18.4% | 27.2% | 15.8% | 10.9% | 20.0% | 10.8% | 21.3% |
| — | -92.4% | -18.7% | -200.4% | +7.0% | +275.3% | +51.5% | +243.8% | -0.0% | -27.2% | -36.6% | -116.8% | +25.8% | +22.8% | -8.1% | +150.3% | -25.9% | -18.2% | +13.4% | -0.4% | +8.0% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 10.4% | 0.5% | 2.2% | -1.1% | 3.9% | 5.4% | 2.5% | 0.7% | 3.9% | 1.5% | 1.5% | -0.8% | 3.5% | 1.9% | 2.7% | 4.2% | 2.9% | 1.7% | 2.9% | 1.7% | 3.6% |
| — | -91.2% | -9.4% | -266.7% | +1.1% | +260.5% | +61.4% | +187.8% | +11.4% | -22.0% | -42.6% | -117.7% | +18.9% | +15.7% | -8.8% | +148.9% | -20.1% | -12.5% | +17.4% | +1.9% | +18.6% | |
| ROA | 6.0% | 0.3% | 1.3% | -0.6% | 2.2% | 3.1% | 1.4% | 0.4% | — | 0.9% | — | -0.4% | — | 1.1% | — | 2.5% | — | 1.0% | — | 0.9% | — |
| — | -91.3% | -10.4% | -264.2% | — | +257.6% | — | +186.6% | — | -25.1% | — | -117.9% | — | +18.7% | — | +161.2% | — | -10.5% | — | +1.4% | — | |
| ROIC | 8.3% | 2.1% | 2.0% | -0.9% | 3.3% | 1.3% | 1.9% | 0.5% | 3.5% | 1.4% | 1.1% | 0.3% | 2.9% | 1.6% | 2.2% | 3.8% | 2.5% | 1.3% | 2.2% | 1.4% | 3.1% |
| — | +52.7% | +3.9% | -289.4% | -4.7% | -2.8% | +72.0% | +55.1% | +20.8% | -13.9% | -48.6% | -91.8% | +15.7% | +23.0% | -3.9% | +166.2% | -18.6% | -14.9% | +8.8% | -2.0% | +23.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.28 | 0.34 | 0.27 | 0.28 | 0.30 | 0.32 | 0.28 | 0.23 | — | 0.33 | — | 0.25 | — | 0.29 | — | 0.28 | — | 0.30 | — | 0.32 | — |
| — | +6.9% | -3.2% | +23.3% | — | -3.7% | — | -8.5% | — | +14.2% | — | -10.9% | — | -3.2% | — | -13.1% | — | -12.8% | — | -13.4% | — | |
| Debt / EBITDA | 1.33 | 8.03 | 7.14 | 21.77 | 5.33 | 12.03 | 8.00 | 22.90 | — | 11.48 | — | 20.39 | — | 8.74 | — | 4.43 | — | 11.22 | — | 11.85 | — |
| — | -33.3% | -10.7% | -4.9% | — | +4.9% | — | +12.3% | — | +31.3% | — | +360.0% | — | -22.1% | — | -62.6% | — | +0.6% | — | +72.3% | — | |
| Current Ratio | 1.09 | 0.99 | 1.01 | 1.09 | 1.06 | 1.27 | 1.37 | 1.46 | — | 1.00 | — | 1.27 | — | 1.21 | — | 1.42 | — | 1.29 | — | 1.44 | — |
| — | -22.5% | -26.4% | -25.2% | — | +27.2% | — | +15.3% | — | -17.3% | — | -10.8% | — | -5.8% | — | -1.1% | — | -16.7% | — | -18.0% | — | |
| Quick Ratio | 0.73 | 0.23 | 0.22 | 0.73 | 0.30 | 0.94 | 0.69 | 1.14 | — | 0.65 | — | 0.87 | — | 0.81 | — | 1.05 | — | 0.86 | — | 1.03 | — |
| — | -75.4% | -67.7% | -35.7% | — | +45.4% | — | +31.1% | — | -19.8% | — | -17.1% | — | -6.2% | — | +1.9% | — | -18.6% | — | -22.1% | — | |
| Interest Coverage | 10.86 | 3.92 | 12.25 | 18.40 | 16.46 | 7.50 | 11.13 | 1.17 | 13.72 | 5.02 | 5.60 | -0.51 | 10.55 | 8.54 | 15.62 | 20.73 | 26.95 | 7.92 | 27.35 | 8.51 | 34.87 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SNY stock.
Sanofi's current P/E is 11.3x. The average P/E over the last 3 quarters is 34.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Sanofi's current operating margin is 20.5%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Sanofi's business trajectory between earnings reports.